Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|November 1, 2005
- Pharmaceutical Executive-11-01-2005
- Volume 0
- Issue 0
Turkey
Author(s)Frederic Boucheseiche
Sponsored and produced by Focus Reports.
Advertisement
Articles in this issue
almost 21 years ago
RX Club Award 2005 Coveragealmost 21 years ago
Marketing to Professionals: Detailingalmost 21 years ago
Opinion: It's All Relativealmost 21 years ago
Thought Leader: A Q&A with Steve Rauschkolbalmost 21 years ago
From the Editor: Lost Worldalmost 21 years ago
Washington Report: Out of Commission? Crawford Steps Downalmost 21 years ago
Valeant Pharmaceuticals is Soldiering Onalmost 21 years ago
Global Report: Drug Evaluation in the UKalmost 21 years ago
Legal: State Compulsory LicensesAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Rebuilding Clinical Data Workflows for the AI Era
5